515 related articles for article (PubMed ID: 1847582)
21. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy.
Adachi JD; Sargeant EJ; Sagle MA; Lamont D; Fawcett PD; Bensen WG; McQueen M; Nazir DJ; Goldsmith CH
Br J Obstet Gynaecol; 1997 Jan; 104(1):64-70. PubMed ID: 8988699
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.
Greenspan SL; Resnick NM; Parker RA
JAMA; 2003 May; 289(19):2525-33. PubMed ID: 12759324
[TBL] [Abstract][Full Text] [Related]
23. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women.
Weinstein RS; Parfitt AM; Marcus R; Greenwald M; Crans G; Muchmore DB
Osteoporos Int; 2003 Oct; 14(10):814-22. PubMed ID: 14610642
[TBL] [Abstract][Full Text] [Related]
24. Biological effects of hormone replacement therapy in relation to serum estradiol levels.
Yasui T; Uemura H; Tezuka M; Yamada M; Irahara M; Miura M; Aono T
Horm Res; 2001; 56(1-2):38-44. PubMed ID: 11815726
[TBL] [Abstract][Full Text] [Related]
25. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women.
Farr JN; Khosla S; Miyabara Y; Miller VM; Kearns AE
J Clin Endocrinol Metab; 2013 Feb; 98(2):E249-57. PubMed ID: 23322818
[TBL] [Abstract][Full Text] [Related]
26. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months.
Hergenroeder AC; Smith EO; Shypailo R; Jones LA; Klish WJ; Ellis K
Am J Obstet Gynecol; 1997 May; 176(5):1017-25. PubMed ID: 9166162
[TBL] [Abstract][Full Text] [Related]
27. Oral contraceptive pills, gonadotropin-releasing hormone agonists, or use in combination for treatment of hirsutism: a clinical research center study.
Carr BR; Breslau NA; Givens C; Byrd W; Barnett-Hamm C; Marshburn PB
J Clin Endocrinol Metab; 1995 Apr; 80(4):1169-78. PubMed ID: 7714086
[TBL] [Abstract][Full Text] [Related]
28. [Absence of antiosteopenic effect of hormone replacement therapy in postmenopausal women].
Ortiz Núñez DA; Mengchún López G; Hernández Marín I; Mendoza R; Ayala Ruíz AR
Ginecol Obstet Mex; 2004 Jul; 72():349-55. PubMed ID: 15469174
[TBL] [Abstract][Full Text] [Related]
29. Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.
Barnes RB; Roy S; Lobo RA
Obstet Gynecol; 1985 Aug; 66(2):216-9. PubMed ID: 2991832
[TBL] [Abstract][Full Text] [Related]
30. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.
Christiansen C; Riis BJ
J Clin Endocrinol Metab; 1990 Oct; 71(4):836-41. PubMed ID: 2205624
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate.
Cundy T; Ames R; Horne A; Clearwater J; Roberts H; Gamble G; Reid IR
J Clin Endocrinol Metab; 2003 Jan; 88(1):78-81. PubMed ID: 12519833
[TBL] [Abstract][Full Text] [Related]
32. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins.
Webber CE; Blake JM; Chambers LF; Roberts JG
Maturitas; 1994 May; 19(1):13-23. PubMed ID: 7935028
[TBL] [Abstract][Full Text] [Related]
33. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
34. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
JAMA; 1995 Jan; 273(3):199-208. PubMed ID: 7807658
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy.
Alexandersen P; Riis BJ; Stakkestad JA; Delmas PD; Christiansen C
J Clin Endocrinol Metab; 2001 Feb; 86(2):755-60. PubMed ID: 11158042
[TBL] [Abstract][Full Text] [Related]
36. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
[TBL] [Abstract][Full Text] [Related]
37. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
38. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study.
Pacifici R; McMurtry C; Vered I; Rupich R; Avioli LV
J Clin Endocrinol Metab; 1988 Apr; 66(4):747-53. PubMed ID: 3126214
[TBL] [Abstract][Full Text] [Related]
39. A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clinical symptoms and lipoprotein lipids.
Sherwin BB; Gelfand MM
Obstet Gynecol; 1989 May; 73(5 Pt 1):759-66. PubMed ID: 2704504
[TBL] [Abstract][Full Text] [Related]
40. Individual and combined effects of estrogen/progestin therapy and lovastatin on lipids and flow-mediated vasodilation in postmenopausal women with coronary artery disease.
Herrington DM; Werbel BL; Riley WA; Pusser BE; Morgan TM
J Am Coll Cardiol; 1999 Jun; 33(7):2030-7. PubMed ID: 10362210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
